Homepage

Driving groundbreaking research. Improving lives.

Helping people with an MPN live a better quality of life as we work toward answers to prevention, progression and a cure for polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) – blood cancers collectively known as myeloproliferative neoplasms.

MPNRF By the Numbers

$ 0 M
MPN RESEARCH FUNDED
0
RESEARCHERS SUPPORTED
0
PROJECTS FUNDED

What is Primary Myelofibrosis (MF)?

Primary Myelofibrosis (MF)

PMF is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells.

Learn more about MF

What is Essential Thrombocythemia (ET)?

Essential Thrombocythemia (ET)

Most commonly diagnosed in women over the age of 50, ET is associated with a proliferation of platelet precursors in the bone marrow and complications frequently include blood clotting and/or bleeding.

Learn more about ET

What is Polycythemia Vera (PV)

Polycythemia Vera (PV)

The disease is most common in men over the age of 60, but anyone can develop PV. PV patients typically experience an elevated red blood cell count, an elevated platelet count and an enlarged spleen, especially over time.

Learn more about PV

Recent News

  • Patients and Caregivers Playing an Active Role in MPN Research

    MPN NEWS | March 18, 2024

    Today, it is more common for patients to be involved with drug developers as they progress through the various stages of bringing a new therapy to market. MPN Research Foundation is committed to ensuring that patient participation is more than a ticked box for drug approval. We actively work to incorporate the patient voice and… Read More »Patients and Caregivers Playing an Active Role in MPN Research

    READ MORE

    UK Study Details Skin Cancer Risks for MPN Patients

    MPN NEWS | March 15, 2024

    Several studies have confirmed the association of ruxolitinib (a JAK inhibitor) with increased risk of non-melanoma skin cancers (NMSCs). A study published in a January 2024 issue of the journal Blood reports on just how serious the risks might be, specifically among patients living with essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). And… Read More »UK Study Details Skin Cancer Risks for MPN Patients

    READ MORE

    Who Develops Which MPN and Why?

    MPN NEWS | March 15, 2024

      Jyoti Nangalia, PhD, Wellcome Sanger Institute It is known that JAK2 mutations are found in “healthy” people around the world, particularly in older individuals. Most of them don’t acquire characteristics of myeloproliferative neoplasms (MPNs). The question is why do some people with the mutation develop an MPN while others don’t. Researchers from the Wellcome… Read More »Who Develops Which MPN and Why?

    READ MORE
  • Ready to do more?

    Julie and her family joined team MPN and created HikeMF to join the fight against MPNs.

    Stay Connected

    With an investment today, you can accelerate research for better outcomes.

    By supporting MPN Research Foundation, you’re also supporting countless doctors and researchers around the world who are working to find a cure for these rare diseases.

     INVEST NOW

    Want to learn more about MPNs? Be the first to know about what’s going on in the PV, ET, and MF community.
    Get our monthly update,
    “Under the Microscope”